secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-085887
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q2 revenues $1.585B (-1% as-reported, +5% ex-FX); adj EPS $1.25; FY guidance narrowed
--------------------------------------------------------------------------------

- Q2 revenues $1,585M, down 1% as-reported but up 5% ex-FX vs Q2 2021; diluted EPS $0.92, adj diluted EPS $1.25 (both include -$0.30 IPR&D).
- Adjusted EBITDA $512M (32.3% margin), inclusive of $97M acquired IPR&D and milestones.
- Board declares quarterly dividend $0.28/share (unchanged).
- Full-year 2022 revenue guidance narrowed to $6.1B-$6.3B; adj EBITDA margin 32%-34% reflecting FX and IPR&D.
- Biosimilars revenue +42% ex-FX; Established Brands +4% ex-FX; Women's Health +1% ex-FX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922085887/0001104659-22-085887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922085887/tm2222382d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer